Stem cell injections to slow vision loss in retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests whether stem cell–based injections near the eye can slow vision loss in people with retinitis pigmentosa. It compares stem cells made from umbilical cord tissue and asks participants to complete several eye tests over time to measure vision changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have retinitis pigmentosa with vision better than 20/100
- Your eye test (ERG) shows conical cell function above a set threshold
- Your measured visual field is larger than 10 degrees
- You can and agree to sign informed consent for research
- You agree to have peribulbar injections (near the eye) using umbilical cord stem cells
- You can attend all scheduled visits and complete eye testing (including ERG and OCT) and quality-of-life surveys
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a stem cell treatment is safe over the long term for people with retinitis pigmentosa. You would get an injection near the eye and then do several follow-up eye tests and quality-of-life surveys to monitor effects.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
This program tests an experimental gene therapy for adults with retinitis pigmentosa (RP), an inherited eye disease that causes vision loss. It aims to see if the treatment can help preserve or improve vision.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.